A group of 105 women (54 of whom were, and had only ever been, taking valproate for at least a year, and 51 who had only ever taken either lamotrigine or carbamazepine, for at least a year) were compared with a group of 50 women who did not have epilepsy: any oral contraceptive taken at the time of testing was recorded and blood levels of follicle stimulating hormone (FSH), luteinising hormone (LH), testosterone and prolactin were estimated from days 2 to 6 of the menstrual cycle (day 1 being the first day of bleeding) and an MRI scan made of their pelvis. Women with epilepsy in general were significantly more likely to exhibit evidence on MRI scanning, of polycystic ovaries (PCO): women taking valproate but not an oral contraceptive were significantly more likely to have clinical biochemical evidence of the polycystic ovarian syndrome (PCOS) with raised LH and/or testosterone levels between days 2 and 6 of their menstrual cycle than women who did not have epilepsy: this was not so for women taking lamotrigine or carbamazepine. Since the polycystic ovary syndrome has potentially serious consequences it is suggested that, where possible, valproate is avoided in women of child bearing potential.
INTRODUCTION
There is a great deal of controversy about whether or not women with epilepsy of child bearing age differ from women who do not have epilepsy. There seems little doubt that women with epilepsy, if other factors are taken into account, have a significantly lower fertility rate than women without epilepsy and possibly, therefore, some factor to account for it 1 . But if this is so (and the study that showed it was sturdy and reliable and generally believed) the explanation, so far, escapes us.
Could the explanation lie in the effect of epilepsy on the menstrual cycle itself? There is some confusing evidence for this 2 . Or could the explanation lie in the effect of various anticonvulsants on the menstrual cycle? There is some even more confusing evidence that this may (or may not) be so, reviewed from a gynaecological perspective in an accompanying article 2 .
The evidence here is even more confusing: some of the reasons, but not all, are described in the accompanying paper 2 . Others have been discussed elsewhere 3 . For a general review of the current beliefs on the relationship between ovarian structure and function and epilepsy see our previous paper in Seizure 3 and the best practice guidelines on managing women with epilepsy 4 .
The question to be determined is whether there is any good evidence that epilepsy itself affects the menstrual cycle or leads to an increased incidence of menstrual irregularity or whether medication used to treat epilepsy might do this. The evidence is conflicting, and both epilepsy itself and its treatment may well do so 3 . In particular, one anticonvulsant drug, sodium valproate, has been suggested to increase the incidence of both polycystic ovaries (PCO) and the polycystic ovary syndrome (PCOS) [5] [6] [7] . However, there is much wrong with these studies. They are difficult to understand and, particularly in the last study, the numbers are small: there is a strong possibility of bias, particularly in the valproate group and not all of the patients had only ever taken just one anticonvulsant drug. Certainly other studies (reviewed by Reference 2) do not support the view that valproate is particularly associated with polycystic ovaries or the polycystic ovary syndrome (since the two are not the same). However, to be certain (since the suspicion remains that valproate may be associated with the polycystic ovary syndrome or polycystic ovaries) further evidence is needed in a study which tries, as far as possible, to control for or obviate the various factors that go to make up the polycystic ovary syndrome.
First of all, what is meant by polycystic ovaries, and the polycystic ovary syndrome? Here we run into an immediate difficulty. The terms are used differently in Europe and the United States (and 'polyfollicular' is sometimes used instead of 'polycystic' in Europewe happen to think more correctly 8 ). A polycystic (or polyfollicular) ovary is detected by scanning (usually by ultrasound-although MRI is probably more accurate-see References 3, 9) . Therefore, if scanning is not part of the investigation-as is often the case in the States-the term polycystic ovary becomes meaningless. In Europe, a polycystic ovary is arbitrarily defined as one which has 10 or more cysts visible on scanning (so, for instance, an ovary with 9 cysts is not polycystic whereas an ovary with 10, is). The other factor is, of course, time: one may have polycystic ovaries 1 month, and normal ones the next, as some cysts disappear. So the term is rather arbitrary: the important thing is that apart from an unusual number of cysts the ovary is behaving normally and there are no associated hormonal or other abnormalities 8 .
The polycystic ovary syndrome also has varying definitions but implies that there is a definite hormonal abnormality (when measured at the right time of the month-an important point) with sometimes other clinical evidence of ovarian dysfunction (e.g. weight gain, irregular periods, etc. 8 ). However, providing there is a definite hormonal abnormality, there do not have to be other symptoms or signs. The hormonal abnormalities that all experts recognise are, at the right time in the month (1) an absolutely raised luteinising hormone level, (2) a raised LH level compared with the follicular stimulating hormone level (reversed ratio), (3) a raised testosterone level, (4) a consistently raised prolactin level. This last can have other explanations and most authorities would be unlikely to accept it on its own as due to the polycystic ovary syndrome unless it could proved to be consistent and not due to other causes 8 .
Levels of luteinising hormone (LH) and follicle stimulating hormone (FSH) vary throughout the menstrual month and so can only be considered as abnormal if they are measured at a specific known time. This is taken to be between days 2 and 6 of the menstrual cycle, day 1 being the first day of bleeding. At this easily measurable stage of the cycle (particularly in irregular cycles) both levels are low. Thereafter they rise, peak at ovulation and then fall (unless pregnancy occurs) 8 . A high level of either hormone measured just after menstruation starts is abnormal 8 . Testosterone and prolactin levels do not fluctuate much throughout the cycle, although testosterone has a diurnal variation and is best measured at the same time of day. In women who are not menstruating at all it does not matter when the blood is taken (although it would be necessary to make sure the woman does have persistent amenorrhoea and is not pregnant): there are several causes of this state. Sadly, some papers on the relationship between antiepileptic medication and menstruation do not mention when in the cycle the blood was taken and one is left to presume it was taken at the right time in the month 3 .
In most of the papers, too, it is not always clear whether the women are just taking the AED under scrutiny, and had only ever taken it, or whether they are taking other AEDs currently, or were in the past. If one is to clearly elucidate the effect of AEDs on the menstrual cycle it would be important to use women who have only ever taken the one AED in question. In addition, since they have their own effect, it is necessary to determine whether the woman is currently taking an oral contraceptive or not at the time of testing.
We, therefore, determined to try to discover whether there was a significant difference between the chemistry of the menstrual cycles of women who had only ever taken valproate and women who had only ever taken either lamotrigine or carbamazepine, but had never taken valproate. To keep the comparison as tight as possible we would only consider women who had primary generalised epilepsy: although there is evidence that endocrine abnormalities are common in women with partial onset epilepsy 10 they are also said to be common in women with primary generalised epilepsy 11 . Women with primary generalised epilepsy are more likely to have only ever taken one anticonvulsant and are extremely unlikely to have structural causes for their seizures, making comparison easier.
In addition 50 normal women, without epilepsy, would be compared with the epilepsy groups. Initially it had been hoped to compare 50 women who had only ever taken valproate with 50 women who had only ever taken lamotrigine, but this proved difficult to accomplish in the 2 years given to the project so we included ever only carbamazepine takers as well. So we end up with three groups: those women who are taking and have only ever taken valproate; those who are taking and have only ever taken either lamotrigine or carbamazepine (there is no difference at all between these two groups in any parameter); and 50 normal women, who do not and who never have, had epilepsy. All the women with epilepsy have primary generalised epilepsy and have been taking their particular anticonvulsant for at least a year. Women with epilepsy were obtained from new patients attending the Birmingham University Seizure Clinic situated in the Queen Elizabeth Psychiatric Hospital in Birmingham: normal women came from students and staff of the Queen Elizabeth Psychiatric Hospital, and the Universities of Birmingham and Aston.
From each subject (those on an anticonvulsant and those not) blood was taken (in the morning) between days 2 and 6 of the menstrual cycle for full blood count, biochemical profile, thyroid function tests and estimation of LH, FSH, testosterone and prolactin. At the same time they had an MRI of the pelvis at the adjacent Nuffield Centre all of which were read and reported blind to the other data. The results were tabulated and calculated. Those with dubious or potentially dangerous scans were re-scanned as needed (including ultrasound scans) and referred to the Women's Hospital service if necessary. No scans turned out to be malignant in the end. We excluded from our survey women who were not menstruating at all: there were five potentially in the valproate group and one in the normal group-all were excluded from the study. The reason that more than 50 patients were included in the two anticonvulsant groups was that, after identification, it took some time to obtain the blood at the right time of the month in some patients, so more patients were included in these groups than 50.
RESULTS
We first measured the prevalence of polycystic ovaries based on MRI criteria (European definition) in the three groups (valproate, lamotrigine or carbamazepine, no epilepsy; Table 1a-d).
These tables strongly suggest that the prevalence of polycystic ovaries is significantly higher in the epilepsy group, although within group comparison Table 1c ). Between groups: no significant differences between three groups taking the OCP. λ 2 for three independent samples (VPA, LTG/CBZ, normal) in those not on OCP P =< 0.001. This again is due to differences between epilepsy and normal (P =< 0.001 by Fisher's Exact test). Within groups: VPA-pill versus no pill-P = 0.001 (λ 2 for two independent samples), therefore women taking VPA have greater chance of PCO if not on OCP. LTG/CBZ-pill versus no pill-no significant difference. Normal-pill versus no pill-no significant difference. suggests this is more, but not completely, in the valproate group; the pill may well protect women with epilepsy from having polycystic ovaries, although, as previously remarked, the significance of polycystic ovaries without other evidence of ovarian dysfunction is open to question, and is only found in the European Classification.
We now look at the polycystic ovary syndrome defined (in the American way 8 ) as hormonal evidence of the syndrome with, or without historical evidence of ovarian pathology-raised LH at the right time of the month and/or raised testosterone levels. The very rare finding of raised prolactin on its own was not taken as evidence of the polycystic ovary syndrome. Table 2a suggests that the greatest proportion of the polycystic ovary syndrome is to be found in the epilepsy group whilst Table 2b confirms that taking an oral Between groups: no pill-λ 2 for three independent samples P = 0.010. VPA versus LTG/CBZ P = 0.002 (λ 2 ), therefore if not taking pill and on VPA then have greater chance of PCOS (Fishers = 0.003). No significant difference between epilepsy and normal groups. Pill: no significant differences between any groups (so pill protects in VPA group). Within groups: no significant differences between the pill and no pill subsets within each treatment group.
contraceptive protects against the syndrome, even in the epilepsy group, but that women taking valproate, but not taking an oral contraceptive, are significantly more likely to have the polycystic ovary syndrome. An oral contraceptive does seem to protect against the syndrome in the epilepsy group, but not signifi- cantly in the non-epilepsy group. The difference does seem confined to the valproate non-pill group, and strongly suggests that this group of patients is significantly more likely to have the polycystic epilepsy syndrome.
The overall biochemical effects are minimal (Table 3a -d) and most are probably related to oral contraceptive use but the group with clinical evidence of the polycystic ovary syndrome is obviously different in terms of the hormonal effect of the syndrome (Table 3e) .
Interestingly, the valproate polycystic ovary group has abnormalities in both testosterone and LH levels; the other polycystic ovary group in the normal population only significantly so in testosterone-but the numbers are small (Table 3f) .
The valproate group is slightly, but significantly older than either of the other two groups (Table 4a and b) (that are indistinguishable in terms of age). When older and younger valproate group members are compared, however (Tables 5 and 6 ) abnormalities are only significant in the younger group. This suggests that the effect of valproate in causing the polycystic ovary syndrome may be confined to the younger (particularly adolescent) patient, particularly in those not taking the oral contraceptive.
Owing to an oversight not all weights and heights were permanently recorded in the epilepsy group-but the majority suggests that there was no great difference Between epilepsy and normal P = 0.004 (t-test).
in body mass index between the patients in the three groups. If one wanted to be sure that a patient with primary generalised epilepsy on valproate did not have the polycystic ovary syndrome, it would be necessary to measure LH, FSH, testosterone and prolactin at the right time of the cycle. In a group of young women therefore of whom 105 were taking, and had only ever taken, one antiepileptic preparation (54 valproate, 51 lamotrigine (30) or carbamazepine (21), and 50 who did not have epilepsy Between treatment groups: <25 group no significant difference between two treatment groups. ≥25 group no significant difference between two treatment groups. Within treatment groups: VPA, no significant difference between two age groups; LTG/CBZ, no significant difference between two age groups. and who had never taken an anticonvulsant, some of whom were taking an oral contraceptive and some of whom were not, the only significant differences were that women, especially younger women, taking valproate and not taking an oral contraceptive were significantly (P = 0.003) more likely to have the polycystic ovary syndrome. All women with epilepsy, if they were not taking the oral contraceptive, were significantly more likely to have polycystic ovaries than women who did not have epilepsy.
DISCUSSION
We have shown three things fairly convincingly. The first is that women with epilepsy, particularly if they are not taking an oral contraceptive, are more likely than women who do not have epilepsy to have polycystic (or polyfollicular) ovaries in the European definition. Secondly, women with epilepsy who are not taking an oral contraceptive are significantly more likely to have the polycystic ovary syndrome if they have only ever taken valproate (but not lamotrigine or carbamazepine) (P = 0.003). This significance disappears if women are taking the pill, suggesting as our third finding that the oral contraceptive protects against the polycystic ovary in women who take valproate as their anticonvulsant.
Thus we have partly (but not completely) proved the findings of Isojärvi. Valproate would seem to, if the oral contraceptive is not involved, significantly increase the proportion of women with the polycystic ovary syndrome (with impaired fertility and the prospect, in later life, of possible diabetes and cancer of the ovary 3 ). If the woman is taking the oral contraceptive she is protected to a large extent against the polycystic ovary syndrome, but obviously, whilst taking the oral contraceptive will not get pregnant. The reason why the polycystic ovary syndrome is significantly commoner in women taking valproate as their anticonvulsant probably is due to valproate being the only anticonvulsant to be associated with an increase in insulin resistance, which is one of the many factors to be associated with the polycystic ovary syndrome 3, 8 .
This finding confirms our previous view 3 . Women with epilepsy who wish sometime to become pregnant, and most women do, should avoid valproate if at all possible unless no other anticonvulsant will prevent seizures. In women with primary generalised epilepsy lamotrigine (or, sometimes, levetiracetam) is usually an acceptable alternative or substitute. We will show, in a separate later paper that 84% of women can be successfully switched to lamotrigine from valproate (and almost all the ones unsuccessful in that transition can be transferred to levetiracetam). The transition is a slow difficult one and it is better to start with lamotrigine if at all possible, rather than substitute later (see Reference 12) .
